J&J’s TAR-200 Misses On Aim To Disrupt Muscle-Invasive Bladder Cancer

 
• By Jessica Merrill
  
missed arrow
A Phase III trial testing TAR-200 missed on efficacy • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas